Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM

Nitesh sinha October 18, 2023

https://ift.tt/N5FdVen

from Sanofi - Aventis Groupe https://ift.tt/3RdVSBj
via IFTTT

health care